Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: A population-based outcome study

Chest

Volumn 136, Issue 6, 2009, Pages 1503-1513

  Le Tourneau, Thierry ^a   Lim, Vanessa ^a   Inamo, Jocelyn ^a   Miller, Fletcher A ^a   Mahoney, Douglas W ^a   Schaff, Hartzell V ^a   Enriquez Sarano, Maurice ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; EMBOLISM; ENDOCARDITIS; FEMALE; FOLLOW UP; HAZARD RATIO; HEART SURGERY; HUMAN; IMPLANTATION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE PROSTHESIS; MITRAL VALVE REPLACEMENT; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTHESIS FAILURE; PROTHROMBIN TIME; RISK; THROMBOEMBOLISM; TREATMENT DURATION; UNITED STATES;

EID: 73149105505     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-1233     Document Type: Article

References (46)

1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368:1005-1011
2. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006; 48:e1-e148
3. Hering D, Piper C, Bergemann R, et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German experience with low-intensity anticoagulation study. Chest 2005; 127:53-59
4. Kuntze CE, Blackstone EH, Ebels T. Thromboembolism and mechanical heart valves: a randomized study revisited. Ann Thorac Surg 1998; 66:101-107
5. Grunkemeier GL, Wu Y. "Our complication rates are lower than theirs": statistical critique of heart valve comparisons. J Thorac Cardiovasc Surg 2003; 125:290-300
6. Russo A, Grigioni F, Avierinos JF, et al. Thrombo-embolic complications after surgical correction of mitral regurgitation: incidence, predictors and clinical implications. J Am Coll Cardiol 2008; 51:1203-1211
7. Fuster V, Pumphrey CW, McGoon MD, et al. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. Circulation 1982; 66:I157-I161
8. Bodnar E, Horstkotte D. Potential flaws in the assessment of minor cerebrovascular events after heart valve replacement. J Heart Valve Dis 1993; 2:287-290
9. Murday AJ, Hochstitzky A, Mansfield J, et al. A prospective controlled trial of St. Jude versus Starr Edwards aortic and mitral valve prostheses. Ann Thorac Surg 2003; 76:66-74
10. Acar J, Iung B, Boissel JP, et al. AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996; 94:2107-2112
11. Kuntze CE, Ebels T, Eijgelaar A, et al. Rates of thromboembolism with three different mechanical heart valve prostheses: randomised study. Lancet 1989; 1:514-517
12. Horstkotte D, Haerten K, Herzer JA, et al. Five-year results after randomized mitral valve replacement with Bjork-Shiley, Lillehei-Kaster, and Starr-Edwards prostheses. Thorac Cardiovasc Surg 1983; 31:206-214
13. Butchart EG, Gohlke-Barwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26:2463-2471
14. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333:11-17
15. McGoon MD, Fuster V, McGoon DC, et al. Aortic and mitral valve incompetence: long-term follow-up (10 to 19 years) of patients treated with the Starr-Edwards prosthesis. J Am Coll Cardiol 1984; 3:930-938
16. Saour JN, Sieck JO, Mamo LA, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322:428-432
17. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101:427-431
18. Horstkotte D, Schulte H, Bircks W, et al. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow-up of patients with St. Jude Medical prostheses. J Heart Valve Dis 1993; 2:291-301
19. Wilson DB, Dunn MI, Hassanein K. Low-intensity anticoagulation in mechanical cardiac prosthetic valves. Chest 1991; 100:1553-1557
20. Bryan AJ, Rogers CA, Bayliss K, et al. Prospective randomized comparison of CarboMedics and St. Jude Medical bileaflet mechanical heart valve prostheses: ten-year follow-up. J Thorac Cardiovasc Surg 2007; 133:614-622
21. Koertke H, Zittermann A, Tenderich G, et al. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Eur Heart J 2007; 28:2479-2484
22. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):457S-482S
23. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230-268
24. Jamieson WR, Cartier PC, Allard M, et al. Surgical management of valvular heart disease 2004. Can J Cardiol 2004; 20(suppl):7E-120E
25. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71:266-274
26. Edmunds LH Jr, Clark RE, Cohn LH, et al. Guidelines for reporting morbidity and mortality after cardiac valvular operations: Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity of The American Association for Thoracic Surgery and The Society of Thoracic Surgeons. J Thorac Cardiovasc Surg 1996; 112:708-711
27. Koertke H, Minami K, Boethig D, et al. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003; 108(suppl):II75-II78
28. Koertke H, Zittermann A, Minami K, et al. Low-dose INR self-management: a promising tool to achieve low complication rates after mechanical heart valve replacement. Ann Thorac Surg 2005; 79:1909-1914
29. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study; warfarin optimized outpatient follow-up study group. Ann Intern Med 1993; 118:511-520
30. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124:970-979
31. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69:236-239
32. Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27:373-380
33. Butchart EG, Payne N, Li HH, et al. Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002; 123:715-723
34. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89:635-641
35. Bayliss A, Faber P, Dunning J, et al. What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Interact Cardiovasc Thorac Surg 2007; 6:390-396
36. van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of haemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost 2008; 6:451-456
37. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000; 9:283-292
38. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158:1641-1647
39. Hasenkam JM, Kimose HH, Knudsen L, et al. Self management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997; 11:935-942
40. Ruel M, Masters RG, Rubens FD, et al. Late incidence and determinants of stroke after aortic and mitral valve replacement. Ann Thorac Surg 2004; 78:77-84
41. Acar J, Enriquez-Sarano M, Farah E, et al. Recurrent systemic embolic events with valve prosthesis. Eur Heart J 1984; 5(suppl):33-38
42. Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995; 108(suppl):371S-379S
43. Godje OL, Fischlein T, Adelhard K, et al. Thirty-year results of Starr-Edwards prostheses in the aortic and mitral position. Ann Thorac Surg 1997; 63:613-619
44. Kafsi N, Trabelsi S, Acar P, et al. Comparison of long-term results of the Starr and Saint-Jude mitral valve prostheses. Arch Mal Coeur Vaiss 1991; 84:1523-1527
45. Macmanus Q, Grunkemeier GL, Lambert LE, et al. Noncloth-covered caged-ball prostheses: the second decade. J Thorac Cardiovasc Surg 1978; 76:788-794
46. John S, Ravikumar E, John CN, et al. 25-year experience with 456 combined mitral and aortic valve replacement for rheumatic heart disease. Ann Thorac Surg 2000; 69:1167-1172